(HHT) |
| 0 (0%) 07-14 02:43 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 39.94 |
| Resistance 1: | 38.74 |
| Pivot price: | 38.70 |
| Support 1: | 36.79 |
| Support 2: | 30.61 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 2.650 |
| Book Value | 36.630 |
| PEG Ratio | 0.61 |
| Gross Profit | 21.527 |
| Profit Margin (%) | 12.76 |
| Operating Margin (%) | 16.89 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 7.6 |
Company news
Thu, 09 Jul 2026
University Hospitals of Leuven Achieves Cure HHT Center of Excellence Designation - The National Law Review
Fri, 01 May 2026
Images in Medicine: Recognizing Hereditary Hemorrhagic Telangiectasia Through Mucocutaneous Findings and Its Management Challenges - Cureus
Wed, 08 Apr 2026
Advocating for Expanded Access to Care: Miller School Leaders Take HHT Awareness to Capitol Hill - University of Miami
Thu, 05 Mar 2026
Atavistik bags another $40M to advance drug for rare vascular disease - FirstWord Pharma
Wed, 25 Feb 2026
Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins - Yahoo Finance
Fri, 19 Dec 2025
Atavistik Bio Holds $120 Million Series B Financing to Advance Small Molecule Therapies for HHT and MPNs - Pharmaceutical Executive
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
